MARKET

ARTLW

ARTLW

ARTELO BIOSCIENC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2501
-0.0201
-7.42%
Closed 16:00 09/22 EDT
OPEN
0.1911
PREV CLOSE
0.2701
HIGH
0.2501
LOW
0.1817
VOLUME
3.65K
TURNOVER
--
52 WEEK HIGH
0.9150
52 WEEK LOW
0.0450
MARKET CAP
--
P/E (TTM)
-0.4371
1D
5D
1M
3M
1Y
5Y
Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today annou...
GlobeNewswire · 09/08 12:30
EXCLUSIVE: Artelo Biosciences CEO, Greg Gorgas Now Interviewing On Benzinga's Power Hour Show
Click To Tune In Here: https://www.youtube.com/watch?v=k922EWXuQ6k
Click To Tune In Here:  · 09/07 16:38
Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th
Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoi...
Newsfile · 08/11 20:18
Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD Study further validates Artelo’s strategy to develop a synthetic CBD-cocrystal with enhanced ph...
GlobeNewswire · 08/04 12:30
BRIEF-Artelo Biosciences Says Board Decreased Number Of Its Authorized Directors To Seven
reuters.com · 07/26 12:39
Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021
LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, t...
GlobeNewswire · 07/21 12:30
BRIEF-Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results And Provides Business Update
reuters.com · 07/12 14:35
Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th
LA JOLLA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, t...
GlobeNewswire · 07/07 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARTLW. Analyze the recent business situations of ARTELO BIOSCIENC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About ARTLW
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (the ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. Its programs represent a range of approaches in utilizing the ECS to develop pharmaceuticals for patients with unmet healthcare needs. Its product pipeline includes ART27.13, ART12.11 and ART26.12. ART27.13 is a clinic-ready, potent, peripherally restricted dual synthetic agonist developed for the treatment of cancer-related anorexia and weight loss. ART26.12 is a small molecule inhibitor of Fatty Acid Binding Protein 5 (FABP5), being studied both as a cancer therapeutic and in anxiety-related disorders, including post-traumatic stress disorder (PTSD). ART12.11 is a solid-state composition of cannabidiol (CBD cocrystal) for PTSD and inflammatory bowel diseases.

Webull offers kinds of Artelo Biosciences Inc stock information, including NASDAQ:ARTLW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTLW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARTLW stock methods without spending real money on the virtual paper trading platform.